AtriCure (ATRC) Stock Forecast, Price & News

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AtriCure in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ATRC shares.
View ATRC analyst ratings or view top-rated stocks.

5 Wall Street analysts have issued 1-year target prices for AtriCure's shares. Their ATRC share price forecasts range from $56.00 to $74.00. On average, they anticipate the company's share price to reach $65.00 in the next twelve months. This suggests a possible upside of 48.4% from the stock's current price.
View analysts price targets for ATRC or view top-rated stocks among Wall Street analysts.

AtriCure's stock was trading at $44.38 at the beginning of the year. Since then, ATRC stock has decreased by 1.3% and is now trading at $43.80.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 7th 2023.
View our ATRC earnings forecast.

AtriCure, Inc. (NASDAQ:ATRC) posted its earnings results on Tuesday, July, 25th. The medical device company reported ($0.12) EPS for the quarter, beating analysts' consensus estimates of ($0.27) by $0.15. The medical device company earned $100.92 million during the quarter, compared to analyst estimates of $97.55 million. AtriCure had a negative net margin of 7.67% and a negative trailing twelve-month return on equity of 7.11%. AtriCure's revenue for the quarter was up 19.4% on a year-over-year basis. During the same period last year, the company posted ($0.32) EPS.

ETFs with the largest weight of AtriCure (NASDAQ:ATRC) stock in their portfolio include SPDR S&P Health Care Equipment ETF (XHE), Nuveen Small Cap Select ETF (NSCS), Simplify Health Care ETF (PINK), Harbor Corporate Culture Small Cap ETF (HAPS), Principal Healthcare Innovators ETF (BTEC) and Invesco Nasdaq Future Gen 200 ETF (QQQS).iShares U.S. Medical Devices ETF (IHI).

AtriCure issued an update on its FY 2023 earnings guidance on Tuesday, July, 25th. The company provided earnings per share (EPS) guidance of -$0.94--$0.92 for the period, compared to the consensus estimate of -$1.02. The company issued revenue guidance of $392.00 million-$395.00 million, compared to the consensus revenue estimate of $388.31 million.

38 employees have rated AtriCure Chief Executive Officer Michael Carrel on Glassdoor.com. Michael Carrel has an approval rating of 100% among the company's employees. This puts Michael Carrel in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 93.0% of employees surveyed would recommend working at AtriCure to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other AtriCure investors own include AbbVie (ABBV), Gilead Sciences (GILD), Amgen (AMGN), Vertex Pharmaceuticals (VRTX), Enterprise Products Partners (EPD), Abbott Laboratories (ABT), Neurocrine Biosciences (NBIX), NVIDIA (NVDA), Pfizer (PFE) and Sarepta Therapeutics (SRPT).

AtriCure trades on the NASDAQ under the ticker symbol "ATRC."

Shares of ATRC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ATRC stock can currently be purchased for approximately $43.80.

AtriCure (NASDAQ:ATRC) has a market capitalization of $2.08 billion and generates $330.38 million in revenue each year. The medical device company earns $-46,470,000.00 in net income (profit) each year or ($0.61) on an earnings per share basis.

The company employs 1,050 workers across the globe.

AtriCure's mailing address is 7555 INNOVATION WAY, MASON OH, 45040. The official website for the company is www.atricure.com. The medical device company can be reached via phone at (513) 755-4100, via email at lynn@gilmartinir.com, or via fax at 513-755-4567.